Business description: Abcam

Number of employees: 1,760
Sales by Activity: Abcam
| Fiscal Period: December | 2019 (GBP) | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) |
|---|---|---|---|---|
Sales of Antibodies and Related Products | 260M | 260M | 315M | 362M |
Geographical breakdown of sales: Abcam
| Fiscal Period: December | 2019 (GBP) | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) |
|---|---|---|---|---|
The Americas | - | 112M | 130M | 162M |
EMEA | - | 69.3M | 84.3M | 90.1M |
China | 39.9M | 39.5M | 58.2M | 62.9M |
Rest of Asia | - | 20M | 23.8M | 28.3M |
Japan | 16.9M | 18.8M | 18.7M | 17.9M |
United Kingdom (UK) | 13.6M | - | - | - |
Other Countries | 58.7M | - | - | - |
Germany | 15.2M | - | - | - |
United States (US) | 116M | - | - | - |
Executive Committee: Abcam
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Hirzel
CEO | Chief Executive Officer | 58 | 2014-09-08 |
Markus Lusser
PSD | President | 58 | 2024-03-17 |
Tommy J. Thomas
IRC | Investor Relations Contact | - | 2022-06-26 |
Sun Yi
SAM | Sales & Marketing | - | 2018-09-30 |
Nick Skinner
HRO | Human Resources Officer | - | 2015-12-31 |
Composition of the Board of Directors: Abcam
| Director | Title | Age | Since |
|---|---|---|---|
Alan Hirzel
BRD | Director/Board Member | 58 | 2013-12-31 |
Mara Aspinall
BRD | Director/Board Member | 63 | 2015-09-13 |
Giles Kerr
BRD | Director/Board Member | 67 | 2018-12-11 |
Luba Greenwood
BRD | Director/Board Member | 47 | 2022-09-11 |
Markus Lusser
BRD | Director/Board Member | 58 | 2025-07-28 |
Company details: Abcam

Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.61% | +1.72% | +38.30% | +106.93% | 1,060B | ||
| -0.76% | -0.84% | +35.21% | +62.70% | 623B | ||
| +0.39% | +4.81% | +17.81% | +83.77% | 480B | ||
| -0.29% | -0.99% | +64.79% | +37.06% | 352B | ||
| -2.03% | +1.03% | +22.25% | +42.16% | 345B | ||
| -1.92% | -1.87% | +11.94% | +33.20% | 274B | ||
| -2.36% | -3.16% | -6.95% | +8.68% | 249B | ||
| -1.37% | +0.04% | +38.29% | +52.33% | 223B | ||
| +0.17% | -0.27% | +24.40% | +96.82% | 182B | ||
| Average | -1.07% | -0.48% | +27.34% | +58.18% | 420.89B | |
| Weighted average by Cap. | -1.05% | +0.04% | +30.65% | +68.82% |

















